Taysha Gene Therapies Inc. Common Stock (TSHA)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, conservative finances, and a margin of safety. Taysha fails most of my first tests. It is a clinical-stage gene therapy company with no approved commercial product. In fiscal year 2025, the period ended 2025-12-31, revenue was $9.8M and net loss was $109.0M, or diluted EPS -$0.34. In fiscal year 2024, the period ended 2024-12-31, revenue was $8.3M and net loss was $89.3M. Losses are not shrinking: in fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $42.4M, or diluted EPS -$0.12, and in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $46.6M, or diluted EPS -$0.13. That is not a compounding machine; it is a cash-consuming research operation. Free cash flow is -$135.6M on a trailing twelve-month basis, with a FairStock FCF yield of -11.6%. FairStock calculations show ROE of -47.05% and ROCE of -23.82%, so capital is being consumed. The debt-to-equity ratio of 0.15 is a comfort, and the FairStock Altman Z-Score of 6.96 suggests balance-sheet distress is not immediate. But no moat can be verified. Value rests on AAV programs such as TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy, where clinical and regulatory success is binary. Valuation is nearly impossible on Graham principles. At the $3.58 close on 2026-10-13, market cap is $1.2B, P/B is 4.84, P/E is -8.73, and the FairStock score is 32/100. The 52-week range is $3.55 to $7.30, so price is near the low. FairStock's Lynch category is none because the company has had losses in each of the last four years. I would treat this as speculation, not a proven investment, until the numbers show progress.

In plain English: Taysha Gene Therapies is a small healthcare company working on gene therapies for rare diseases of the brain and nerves. It is still losing money and has no steady profits, so the business looks financially weak today. At $3.58 on 2026-10-13, the price is near its 52-week low, but because there are no real earnings to support it, the stock looks expensive against current losses and more like a bet on future medical trial success than a cheap business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer